Categories
Change Password!
Reset Password!
Published evidence on
phase 2 or phase 3 clinical trials of CRRP-target therapies has shown promising
results. Similar results in further studies can be expected.
Calcitonin gene-related peptide (CGRP)
is a signaling neuropeptide released from activated trigeminal sensory
afferents in a headache and facial pain disorders. There are a handful of
CGRP-targeted treatments currently in phase III studies for an acute migraine
treatment or prevention.
At present, there are four monoclonal antibodies [ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab)] being studied for migraine prevention that target either the CGRP ligand or receptor.
In the meantime, one small-molecule
CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase III studies
for the treatment of migraine. Among these, two of the anti-CGRP monoclonal
antibodies are also in clinical trials for cluster headache prevention. Many
other small-molecular CGRP receptor antagonists are in earlier developmental
stages for the treatment or prevention of an acute migraine. The current review
emphasizes on the growing body of clinical trials studying CGRP-targeted
therapies for migraine and cluster headaches.
Clin Neuropharmacol. 2017 Jun 21.
Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
Schuster NM et al.
Comments (0)